Zanubrutinib

Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA

Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA

SG Tylor

Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...